Monica Adelina Catherine Gultom, Evita Mayasari, Dian Dwi Wahyuni, Ahmad Yafiz Hasby
The Coronavirus disease of 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Doctors may use several laboratory tests, such as the biomarkers for hemostasis alteration, to assess the severity and prognosis of COVID-19 patients. This study aims to determine the association between hemostatic markers [including prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), D-dimer, fibrinogen, platelet]and the clinical spectrum of SARS-CoV-2 infected patients (including moderate and severe COVID-19, and the non-survivors). This retrospective cohort analyzed the hospital medical records of 120 COVID-19 inpatients from January to December 2021 in Medan city, Indonesia. This study revealed a significant association between increasing values of PT/INR, APTT, fibrinogen, D-dimer, and the clinical spectrum of COVID-19 patients.
